(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
1 September 2011 (01.09.2011)

PCT

(10) International Publication Number
WO 2011/106300 A3

(51) **International Patent Classification**:
C07K 16/22 (2006.01) ***A61K 31/337*** (2006.01)
A61K 31/282 (2006.01) ***A61K 39/395*** (2006.01)

(21) **International Application Number**:
PCT/US2011/025651

(22) **International Filing Date**:
22 February 2011 (22.02.2011)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:

61/307,095	23 February 2010 (23.02.2010)	US
61/351,231	3 June 2010 (03.06.2010)	US
61/360,059	30 June 2010 (30.06.2010)	US
61/439,819	4 February 2011 (04.02.2011)	US

(71) **Applicant** *(for all designated States except AL, AT, BA, BE, BG, CH, CN, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IN, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR, US)*: **GENENTECH, INC.** [US/US]; 1 DNA Way, South San Francisco, CA 94080-4990 (US).

(71) **Applicant** *(for all designated States except US)*: **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **DUPONT, Jakob** [US/US]; c/o Genentech, 1 DNA Way, South San Francisco, CA 94080 (US). **IRL, Cornelia** [DE/CH]; Grenzacherstrasse 124, 4070 Basel (CH).

(74) **Agents**: **PLEASURE, Irene, T.** et al.; Genentech, Inc., 1 DNA Way, MS-49, South San Francisco, CA 94080-4990 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) **Date of publication of the international search report**:
15 December 2011

WO 2011/106300 A3

(54) **Title**: ANTI-ANGIOGENESIS THERAPY FOR THE TREATMENT OF OVARIAN CANCER

(57) **Abstract**: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents for the treatment of ovarian cancer.